Celyad Oncology S.A.
CLYYFOTCHealthcare● Active
$0.25
+$0.00(+0.00%)
Market Cap$11190476
P/E Ratio—
52W High$0.53
52W Low$0.15
Celyad Oncology S.A. (CLYYF) · Income Statement
Annual, quarterly, or TTM views · SEC 10-K & 10-Q via FMP · adjust period and M/B/T below.
FMP · CLYYF · as of 2026-06-09
Financial statements
Revenue · Gross Profit · Net Income
| Breakdown | 2025-12 | 2024-12 | 2023-12 | 2022-12 | 2021-12 |
|---|---|---|---|---|---|
| Revenue | |||||
| Revenue | $0.02M | $0.19M | $0.10M | $0.00M | $0.00M |
| Cost of Revenue | ($1.91M) | $0.01M | $0.07M | $1.44M | $1.52M |
| Gross Profit | $1.93M | $0.17M | $0.03M | ($1.44M) | ($1.52M) |
| Gross Margin %(computed) | — | 93.55% | 32.35% | — | — |
| Operating Expenses | |||||
| R&D Expenses | $3.28M | $3.31M | $4.67M | $18.93M | $20.77M |
| G&A Expenses | $0.00M | $3.09M | $5.71M | $10.34M | $9.66M |
| Total Operating Expenses | $9.11M | $6.03M | $8.49M | $20.26M | $26.91M |
| Operating Income | ($7.18M) | ($5.86M) | ($8.46M) | ($40.86M) | ($26.39M) |
| Operating Margin %(computed) | — | — | — | — | — |
| Interest Income | $0.01M | $0.03M | $0.03M | $0.01M | $0.03M |
| Interest Expense | $0.06M | $0.00M | $0.08M | $0.20M | $0.26M |
| Income Before Tax | ($0.66M) | ($5.82M) | ($8.64M) | ($40.87M) | ($26.50M) |
| Income Tax Expense | ($1.49M) | $0.00M | ($0.19M) | $0.07M | $0.01M |
| Net Income | $0.83M | ($5.82M) | ($8.45M) | ($40.94M) | ($26.51M) |
| Net Margin %(computed) | — | — | — | — | — |
| Per Share & EBITDA | |||||
| EPS (Basic) | $0.02 | $-0.14 | $-0.33 | $-1.81 | $-1.70 |
| Wtd Avg Shares | 42.78M | 41.43M | 25.72M | 22.59M | 15.60M |
| EBITDA | ($7.01M) | ($5.69M) | ($7.76M) | ($39.70M) | ($25.41M) |
| EBITDA Margin %(computed) | — | — | — | — | — |
Data source: Financial Modeling Prep · Last updated: 2026-06-09 · EUR · M
Explore more Celyad Oncology S.A. data
About Celyad Oncology S.A. (CLYYF) Income Statement
Celyad Oncology S.A. (CLYYF) income statement data is sourced from SEC Form 10-K and 10-Q filings. For fiscal year 2025, CLYYF reported revenue of $0.00B, gross profit of $0.00B (gross margin 9195.73%), and net income of $0.00B — a net profit margin of 3952.59%.
Frequently asked questions
CLYYF · 4 questionsCelyad Oncology S.A. (CLYYF) reported revenue of $0.00B for 2025, down 88.7% year-over-year.
CLYYF revenueCLYYF salesannual revenue YoYincome statement
· Source: FMP /stable/income-statement · SEC EDGAR Form 10-K & 10-Q · As of 2026-06-09